Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NCT05935358)

🧪 Interventions in This Study

• Nuwiq (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (18 Sites)

• UT Southwestern Medical Center — Dallas, Texas
• University Hospital Centre Zagreb — Zagreb,
• Helsinki University Hospital — Helsinki,
• CHU de Nantes Hôtel-Dieu — Nantes,
• CHRU de Tours — Tours,
• Vivantes Klinikum im Friedrichshein (KFH) — Berlin,
• Gerinnungszentrum Rhein-Ruhr — Duisburg,
• Universitätsklinikum Hamburg Eppendorf (UKE) — Hamburg,
• Christian Medical College Vellore — Vellore, Tamil Nadu
• St. John's Medical College Hospital — Bengaluru,
• Azienda Ospedaliera Pugliese Ciaccio — Catanzaro,
• Azienda Ospedaliero Universitaria Careggi - Centro Emofilia — Florence,
• Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital — Milan,
• Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia — Skopje,
• Clinical Center for Serbia Belgrade — Belgrade,
• Hospital Universitario La Paz — Madrid,
• Hospital Universitario Virgen del Rocio — Seville,
• St. James's University Hospital — Leeds,

📞 Contact the Study Coordinator

Phone: +41 554512141

Email: Sigurd.Knaub@octapharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Severe Hemophilia A

• A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis — Los Angeles, California
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors — Phoenix, Arizona
• A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. — Los Angeles, California

Explore by condition: All Severe Hemophilia A clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.